Antiphospholipid antibody carriers and patients with quiescent antiphospholipid syndrome show persistent subclinical complement activation.

No abstract is available for this paper.

• Publication year

  2023

• Venue

  Rheumatology

• Publication date

  2023-09-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/rheumatology/kead517PMID 37774001
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Beta 2 glycoprotein I and neutrophil extracellular traps: Potential bridge between innate and adaptive immunity in anti-phospholipid syndrome

  2023cited by this paper
• An update on inflammation in antiphospholipid syndrome

  2022cited by this paper
• Circulating immune-complexes of IgG/IgM bound to B2-glycoprotein-I associated with complement consumption and thrombocytopenia in antiphospholipid syndrome

  2022cited by this paper
• Treatment advances in antiphospholipid syndrome: 2022 update.

  2022cited by this paper
• Targeting thromboinflammation in antiphospholipid syndrome.

  2022cited by this paper
• Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the "CAPS Registry".

  2022cited by this paper
• Interaction between Antiphospholipid Antibodies and Protein C Anticoagulant Pathway: A Narrative Review

  2022cited by this paper
• Low Preconception Complement Levels Are Associated with Adverse Pregnancy Outcomes in a Multicenter Study of 260 Pregnancies in 197 Women with Antiphospholipid Syndrome or Carriers of Antiphospholipid Antibodies

  2021cited by this paper
• Markers of complement activation in plasma during quiescent phases in catastrophic antiphospholipid syndrome patients.

  2021cited by this paper
• High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets.

  2021cited by this paper
• Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion.

  2020cited by this paper
• The first thrombotic event in purely obstetric antiphospholipid syndrome patients and in antiphospholipid antibody carriers: comparison of incidence and characteristics

  2020cited by this paper
• Inflammatory markers in thrombosis associated with primary antiphospholipid syndrome

  2020cited by this paper
• Complement activation in the plasma and placentas of women with different subsets of antiphospholipid syndrome

  2019cited by this paper
• Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.

  2019cited by this paper
• Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab.

  2019cited by this paper
• Anti-β2GPI/β2GPI complexes induce platelet activation and promote thrombosis via p38MAPK: a pathway to targeted therapies

  2019cited by this paper
• Absence of Distinct Immunohistochemical Distribution of Annexin A5, C3b, C4d, and C5b-9 in Placentas From Patients With Antiphospholipid Antibodies, Preeclampsia, and Systemic Lupus Erythematosus

  2019cited by this paper
• Blood Cell-Bound C4d as a Marker of Complement Activation in Patients With the Antiphospholipid Syndrome

  2019cited by this paper
• Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS.

  2019cited by this paper
• Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies

  2018cited by this paper
• Eculizumab for catastrophic antiphospholipid syndrome-a case report and literature review.

  2018cited by this paper
• Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications

  2018cited by this paper
• Catastrophic Antiphospholipid Syndrome: Candidate Therapies for a Potentially Lethal Disease.

  2017cited by this paper
• Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery.

  2016cited by this paper
• Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome

  2016cited by this paper
• Delineating the deranged immune system in the antiphospholipid syndrome.

  2016cited by this paper
• Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study.

  2011cited by this paper
• High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome

  2011cited by this paper
• beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation.

  2009cited by this paper
• Update of the guidelines for lupus anticoagulant detection

  2009cited by this paper
• Influence of different IgG anticardiolipin antibody cut‐off values on antiphospholipid syndrome classification

  2008cited by this paper
• Complement activation in patients with primary antiphospholipid syndrome

  2008cited by this paper
• Revised classification criteria for antiphospholipid syndrome and the thrombotic risk in patients with autoimmune diseases

  2007cited by this paper
• International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

  2006cited by this paper

• Complement activation and altered fibrin clot properties in obstetric antiphospholipid syndrome: impact on thromboembolism and pregnancy

  2026cites this paper
• B Cell Tolerance and Obstetric Antiphospholipid Syndrome

  2025cites this paper
• The complement system in autoimmune diseases: pathogenesis, diagnostic markers, and therapeutic strategies

  2025cites this paper
• Complement in antiphospholipid syndrome, time to target?

  2025cites this paper
• Can complement activation be the missing link in antiphospholipid syndrome?

  2024cites this paper